Page 5 - Acelyrin News Today

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that...

Quite a few insiders have dramatically grown their holdings in Acelyrin, Inc. ( NASDAQ:SLRN ) over the past 12 months...

Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $8.91 and last traded at $9.02, with a volume of 560184 shares trading hands. The stock had previously closed at $9.13. Analyst Upgrades and Downgrades SLRN has been the […]

Acelyrin (NASDAQ:SLRN – Free Report) had its price objective reduced by HC Wainwright from $44.00 to $30.00 in a research report report published on Tuesday, MarketBeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Acelyrin’s FY2026 earnings at ($5.11) EPS and FY2027 earnings at ($5.23) EPS. SLRN […]

By Ben Glickman Oracle reported fiscal first-quarter growth in its cloud business slowed sequentially and compared to the year-ago quarter. Oracle's total...

Oracle's revenue outlook disappoints, Apple kicks off its annual fall launch event, Tesla falls a day after surging 10%, and WestRock signs an agreement to...

ACELYRIN, INC. (SLRN) announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa.

By Ben Glickman Shares of Acelyrin fell after-hours after the company said its skin drug candidate's primary endpoint didn't meet statistical significance....

Acelyrin (NASDAQ:SLRN – Free Report) had its price target lifted by Morgan Stanley from $29.00 to $39.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has an overweight rating on the stock. Several other research firms also recently issued reports on SLRN. Piper Sandler assumed coverage on Acelyrin […]

HC Wainwright started coverage on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $44.00 price target on the stock. HC Wainwright also issued estimates for Acelyrin’s Q3 2023 earnings at ($0.29) EPS, Q4 2023 earnings at […]